• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NovaDel Pharma Inc. To Present at Noble Financial Group Small-Cap Conference

Posted on: Friday, 4 November 2005, 09:00 CST

NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company with an oral spray technology applicable to a broad range of therapeutic areas and product categories, will be presenting at the Noble Financial Group Small-Cap Conference in South Florida on November 11, 2005 at 8:15 AM.

Dr. Gary Shangold, NovaDel's Chief Executive Officer, will provide a corporate overview, including an update on NovaDel's product pipeline. NovaDel's novel drug delivery system provides a number of potential benefits, including faster onset of action. All of the product candidates could qualify for the fast-track 505(b)(2) regulatory approval path.

Noble Financial Group (Member NASD, SIPC) - now in its twenty-first year - specializes in small-cap equity research providing institutional investors with detailed corporate analysis, sector and industry studies, road shows, investment banking, market-making, and sales and trading services. The conference, held at the Seminole Hard Rock Hotel & Casino in Hollywood, FL. November 10 & 11, 2005, will feature close to fifty companies across numerous industry sectors. Senior executives will make group presentations to analysts and portfolio managers on their business strategy and outlook and will be available for breakout sessions and one-on-one meetings. Additional conference information can be accessed through the following web link:

http://www.noblefinancialgroup.com/smallcaprock.htm

About NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the development of novel drug delivery systems for prescription and over-the-counter drugs. The Company's proprietary oral spray technology delivery system offers the patient the potential for (i) fast onset of action; (ii) improved drug safety by reducing the required drug dosage and reducing side effects; (iii) improved patient convenience and compliance; and (iv) enhanced dosage reliability. The Company plans to develop such products independently and through collaborative arrangements with major pharmaceutical and biotech companies. To find out more about NovaDel Pharma Inc. (AMEX: NVD), visit our website at www.novadel.com.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein including, but not limited to, the successful completion of its pilot pharmacokinetic feasibility studies, the ability to develop products (independently and through collaborative arrangements), the ability to commercialize and obtain FDA and other regulatory approvals for products under development and the acceptance in the marketplace for lingual spray products. Further, the Company operates in industries where securities may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Important factors that the Company believes might cause such differences are discussed in the risk factors detailed in the Company's most recent Annual Report and Registration Statements, filed with the Securities and Exchange Commission. In assessing forward-looking statements contained herein, if any, the reader is urged to carefully read all cautionary statements contained in such filings.

Source: Business Wire

More News in this Category